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Abstract
Background: MYCT1, a putative target of c-Myc, is a novel candidate tumor suppressor gene cloned from laryngeal
squamous cell carcinoma (LSCC). Its transcriptional regulation and biological effects on LSCC have not been clarified.
Methodology/Principal Findings: Using RACE assay, we cloned a 1106 bp transcript named Myc target 1 transcript variant
1( MYCT1-TV) and confirmed its transcriptional start site was located at 140 bp upstream of the ATG start codon of MYCT1-
TV. Luciferase, electrophoretic mobility shift and chromatin immunoprecipitation assays confirmed c-Myc could regulate the
promoter activity of MYCT1-TV by specifically binding to the E-box elements within 2886 to 2655 bp region. These results
were further verified by site-directed mutagenesis and RNA interference (RNAi) assays. MYCT1-TV and MYCT1 expressed
lower in LSCC than those in paired adjacent normal laryngeal tissues, and overexpression of MYCT1-TV and MYCT1 could
inhibit cell proliferation and invasion and promote apoptosis in LSCC cells.
Conclusions/Significance: Our data indicate that MYCT1-TV, a novel MYCT1 transcript, is regulated by c-Myc and down-
regulation of MYCT1-TV/MYCT1 could contribute to LSCC development and function.
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Introduction
Laryngeal squamous cell carcinoma (LSCC) is the second main
upper respiratory tract tumor behind lung cancer in incidence and
mortality rates [1], and represents the vast majority (approxi-
mately 96%) of laryngeal malignancies [2]. The morbidity of
LSCC shows an increasing trend in China, especially in the
northeast part. The etiology of LSCC is considered to be
multifactorial. The main predisposing factors are tobacco and
alcohol abuse [3]. Despite many advances achieved in the
diagnosis and treatment of the disease, its overall survival rate
has remained unchanged (at approximately 35–70%) over the past
several decades [1]. Therefore, it is necessary to develop new
diagnostic and therapeutic targets for LSCC.
Although much work is presently focused on the research about
the relationship between LSCC and oncogenes, such as BCL2 [4],
c-Myc [4,5] and EGFR [6], or tumor suppressor genes (TSGs), such
as P53 [7], Rb [8], P16 [8] and P21 [8], no information about gene
cloning related to laryngeal carcinoma is reported except human
Myc target 1 (MYCT1) [9].
MYCT1 (Gene ID: 80177) is a novel candidate TSG cloned
using in silicon hybridization and molecular methods from LSCC
by our team, which was previously named MTLC (c-Myc target
from laryngeal cancer cells, GenBank accession No. AF_527367).
The full length of this gene is about 21 kb. It contains two exons
and produces a 1006 bp transcript coding a protein with 235
amino acid residues. Our previously study demonstrated that
MYCT1 existed in various human tissues and was down-regulated
in gastric carcinoma tissues. The 59 flanking sequence of MYCT1
contains two binding sites of oncoprotein c-Myc [9,10]. But
whether it is also down-regulated in LSCC or is really regulated by
c-Myc and its biological effects on LSCC have not been
systematically analyzed. In this present work, we have studied
this candidate c-Myc target gene in greater detail. We cloned a new
MYCT1 transcript variant (MYCT1-TV, GenBank accession
No. GU997693), confirmed its transcriptional start site (TSS) for
the first time, identified a 230 bp region that mediated basal
transcription by two E-box elements and explored the role of
MYCT1 and its variant in the development and aggression of
LSCC by comparing the expression or biological characteristics
between MYCT1 and its isoform in LSCC tissues or cells, which
will lay a foundation for the further exploration on understanding
the function of MYCT1 in c-Myc regulatory subnetwork and
provide us a novel LSCC diagnostic and therapeutic target for the
future study.
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25648Figure 1. cDNA characteristics of MYCT1-TV. cDNA and putative amino acid sequences for MYCT1-TV. The 1106 bp cDNA, obtained by 59 and 39
RACE, contains a putative open reading frame that encodes a polypeptide of 187 amino acid residues. Transcriptional start site is marked in bold and
italic. Initiator codon ATG is boxed.
doi:10.1371/journal.pone.0025648.g001
Figure 2. Comparison of MYCT1-TV and MYCT1. A. The full-length cDNA clones of MYCT1-TV and MYCT1 are 1106 bp and 1006 bp,
respectively. MYCT1-TV has a shorter 59 flanking sequence and a longer 39 flanking sequence compared to MYCT1. B. The amino acids sequence
comparison of MYCT1-TV and MYCT1.
doi:10.1371/journal.pone.0025648.g002
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Cloning and characterization of MYCT1-TV
we obtained a novel 1106 bp transcript variant of MYCT1
named myc target 1 transcript variant 1 (MYCT1-TV, GenBank
accession No. GU997693) using RACE and cDNA cloning
methods. Our sequencing results indicated a potential MYCT1-
TV TSS was located at 140 bp upstream of the ATG start codon
of MYCT1-TV (Fig. 1). Meanwhile, the only TSS we confirmed
was also located at 12 bp downstream of the start nucleotide of the
published MYCT1 mRNA sequence (GenBank accession
No. AF_527367, Fig. 1). MYCT1-TV has a 140 bp 59 untranslated
leader and a 370 bp 39 untranslated region with a 32 bp poly (A)
tail. As predicted using ExPASy proteomics server, the 564 bp
open reading frame codes for a putative protein of 187 amino acid
residues with a predicted molecular mass of 20835Da and pI 10.26
(Fig. 1). Using NCBI blast, we compared the protein and
nucleotide sequences of MYCT1-TV with those of MYCT1
(GenBank accession No. AF_527367). The analysis results re-
vealed that MYCT1-TV cDNA has a shorter 59 flanking sequence
and a longer 39 flanking sequence than MYCT1 (Fig. 2A).
MYCT1-TV protein has a shorter 48 amino acid N-terminus
than MYCT1 protein and the other 187 amino acid protein of
them are much the same (Fig. 2B). ExPASy proteomics server
analysis demonstrated the shorter 48 amino acid protein contains
no obviously structural or functional motif.
Identification and analysis of MYCT1-TV promoter region
Using web software BDGP, Promoter 2.0 and Promoter Scan,
we analyzed the proximal 1033 bp (2981/+52) promoter
sequence of MYCT1-TV and found two core promoter sequences
in this region (Fig. 3A). In order to determine which region play an
important role in promoter activity, we generated a number of
consecutive 59 deletions of MYCT1-TV promoter (Fig. 3B). The
generated fragments were cloned into pGL3-Basic and transiently
co-transfected into Hep2 and HEK293 cells along with pRL-TK.
Luciferase results revealed a 7.26-fold increased transcriptional
activity of P852 as compared to the empty vector in Hep2 cells,
indicating that we obtained an active MYCT1-TV promoter
(p,0.01, Fig. 3B). Removal of 53 bp at 59 end from P852 caused a
Figure 3. Identification and functional characterization of human MYCT1-TV promoter. A. Nucleotide sequence of the promoter region
(from 2981 to +52) of human MYCT1-TV. The putative binding sites for transcriptional factors are underlined and markded as E-box A and B. The
transcriptional start site is marked in bold and italic at 2140 bp. The start nucleotide of the published MYCT1 mRNA sequence is marked in bold at
2152 bp. The positions of putative core promoter sequences are marked with gray color. The numbering of the nucleotides starts at initiator codon
ATG (+1) which are boxed. B. Analysis of human MYCT1-TV promoter activities detected by luciferase assay. Hep2 (black bars) or HEK293 (gray bars)
cells are transiently transfected with 0.8 mg of the deletion constructs together with 16 ng pRL-TK. The relative activities of a series of deletion
constructs are determined by luciferase assay (**, p,0.01; *, p,0.05).
doi:10.1371/journal.pone.0025648.g003
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However, a further deletion of 132 bp at 59 end from P799
caused a drastical drop about 7.16-fold of MYCT1-TV promoter
activity compared to P799 (p,0.01, Fig. 3B). The similar results
were also obtained in HEK293 cells (Fig. 3B). These results
suggested that the basal regulatory elements important for
maximal promoter activity are present between 2852 bp and
2667 bp region, and P852 (2852/+12) acts as the proximal
promoter.
Importance of two E-boxes in MYCT1-TV promoter
activity
C-Myc is known as a transcription factor through forming
heterodimers with its binding partner Max specifically binding to a
canonical consensus DNA sequence CACGTG, termed the E-box
[11]. And it has also been reported to bind to several other
noncanonical DNA motifs, such as CATGTG, CATGCG,
CACGCG, CACGAG, and CAACGTG [12–14]. In luciferase
assay, we confirmed the promoter region between 2852 bp and
2667 bp was important for basal regulatory elements binding. And
two noncanonical E-box elements, CGCATG (the reverse comple-
ment of CATGCG) and CACGCG, as we reported before [9], were
just present in this region (Fig. 3A). To analyze whether these
putative c-Myc/Max-binding sites mediate transcriptional activity of
MYCT1-TV core promoter, we introduced three point mutations,
P852-mutA, P852-mutB and P852-mutAB. Luciferase assay showed
that compared to the wide-type promoter P852 in Hep2 cells,
mutated only E-box A (P852-mutA) or B (P852-mutB) or mutated
both E-box A and B (P852-mutAB) caused a 5.40-fold, 5.28-fold or
5.52-fold reduction of transcriptional activity (p,0.01, Fig. 4). And
there were no significant difference between these mutants (p.0.05,
Fig. 4). Similar results were also obtained in HEK293 cells (Fig. 4).
These results indicated that both of the identified motifs are essential
for the basal activity of MYCT1-TV core promoter.
Regulation of MYCT1-TV promoter by c-Myc
To assess the importance of E-box elements for c-Myc/Max
binding in vitro, we performed EMSA using biotin-labeled,
synthetic double-stranded oligonucleotides corresponding to the
E-box A and B. These probes were incubated with the nuclear
extracts isolated from Hep2 or HEK293 cells. As shown in Fig. 5A
(lanes 2, 7, 13 and 18), both oligonucleotides specific to E-box A
and B were retarded significantly by cell nuclear proteins.
Quantitative competitions for bindings were found at the presence
of a nearly 100-fold excess of unlabeled oligonucleotides (lanes 3,
8, 14 and 19), whereas no competitions were observed with a
nearly 100-fold excess of unlabeled mutant oligonucleotides (lanes
4, 9, 15 and 20). Furthermore, the bands were supershifted by
specific c-Myc antibodies (lanes 5, 10, 12 and 17). The interaction
between c-Myc/Max and MYCT1-TV promoter was further
confirmed by ChIP assay. Using primers to amplify both c-
Myc/Max binding regions of MYCT1-TV promoter, we observed
strong PCR products based on the precipitate by c-Myc antibody
from Hep2 and HEK293 cells, but not from negative control
immunoprecipitations using anti-rabbit IgG antibody (Fig. 5B).
Reduced MYCT1-TV promoter activity with silencing of
c-Myc
To further confirm the role of c-Myc/Max in regulation of
MYCT1-TV promoter activity, we silenced c-Myc translation via
RNA interference. The efficieny of the siRNAs directed against c-
Myc was confirmed by qRT-PCR. As compared to the Mock
control (no siRNA) in Hep2 and HEK293 cells, transfection of c-
Myc specific siRNA effectively knocked down c-Myc mRNA levels
(p,0.05, Fig. 6A) whereas transfection of nonspecific control
siRNA (NC siRNA) showed no evidence of silencing (p.0.05,
Fig. 6A). We then cotransfected the luciferase reporter plasmid
P852 containing MYCT1-TV promoter together with siRNA.
Compared with NC siRNA group, luciferase activity of P852
displayed significant reduction after transfected with c-Myc siRNA
(p,0.01, Fig. 6B). Thus, c-Myc can strongly enhance transcrip-
tional activity of MYCT1-TV promoter.
Extensive expression of MYCT1-TV in human cells
To explore whether MYCT1-TV is widely expression or specific
expression in human cells, we performed RT-PCR in Hep2,
HeLa, BGC823, SGC7901, MKN1, Bel7402, GES1 and
HEK293 cells compared with normal human blood (positive
control). The result showed that the MYCT1-TV extensively
expressed in all cells examined, but MYCT1-TV mRNA levels in
normal cells of GES1 and HEK293, which shared no difference
with normal human blood (p.0.05, Fig. 7A), were significantly
higher than those in tumour cells of Hep2, HeLa, BGC823,
SGC7901, Bel7402 and MKN1 (p,0.01, Fig. 7A). There was also
no significant difference in MYCT1-TV mRNA levels among the
tumour cells above (p.0.05, Fig. 7A).
Reduced expression of MYCT1-TV or MYCT1 in LSCC
tissues
Since MYCT1 was cloned from LSCC and down-regulated in
gastric carcinoma tissues [9,10], we are interested in exploring
whether it is also down-regulated in LSCC and existed the
expression differences between MYCT1-TV and MYCT1 in LSCC.
RT-PCR results showed that both MYCT1-TV and MYCT1
mRNA levels in LSCC tissues were significantly lower than that in
paired adjacent normal laryngeal tissues (p,0.01, Fig. 7B).
Moreover the mRNA expression levels of these two transcripts
showed no significant difference in LSCC or paired adjacent
normal laryngeal tissues (p.0.05, Fig. 7B).
We assessed the expression levels of MYCT1-TV/MYCT1 with
respect to clinical characteristics (age, sex and cancer stage). No
Figure 4. The transcriptional activity of the mutant MYCT1-TV
core promoter. Promoter constructs pGL3-Basic, P852-mutA, P852-
mutB and P852-mutAB were cotransfected with pRL-TK into Hep2
(black bars) or HEK293 (gray bars) cells, respectively by Lipofectamine
2000 Reagent. Luciferase activity was measured at 48 h after
transfection (**, p,0.01).
doi:10.1371/journal.pone.0025648.g004
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MYCT1 with respect to patient age, sex, or patient clinical stage
(p.0.05, Table 1).
Function of MYCT1-TV and MYCT1 in Hep2 and HEK293
cells
To elucidate the function of MYCT1-TV and MYCT1 in human
cells, MYCT1-TV-GFP and MYCT1-GFP expression vectors
were generated and transiently transfected into Hep2 and
HEK293 cells. Forty-eight hours after transfection, Hep2 cells in
MYCT1-TV-GFP and MYCT1-GFP groups showed a significant
increase at mRNA levels compared to those in blank and GFP
groups (p,0.01, Fig. 8A). MYCT1-TV and MYCT1 protein
expression were detected by confocal immunofluorescence mi-
croscopy (Fig. 8B). These results revealed that the transfection is
successful. Similar results were also obtained in HEK293 cells
(Fig. 8A and B).
Cell viability assay showed that the proportion of viable cells in
MYCT1-TV-GFP or MYCT1-GFP group was significantly fewer
than that in GFP group (p,0.05, Fig. 9A). The percentages of
viable cells in MYCT1-TV-GFP, MYCT1-GFP and GFP groups
relative to that in blank group were 41.4666.00%, 46.9165.56%
and 81.2768.61%, respectively. In addition, there was no
significant difference between MYCT1-TV-GFP and MYCT1-
Figure 5. A role for E-box sites in basal human MTCT1-TV promoter activity. A. Binding of MYCT1-TV E-box sites to c-Myc in vitro detected by
EMSAs. The symbol ‘‘ * ’’ means the oligonucleotides labled by biotin. Lanes 1 to 10 stand for the results from Hep2 cells and Lanes 11 to 20 the
results from HEK293 cells. Lanes 1, 6, 11 and 16 represent biotin-labled oligonucleotides. Lanes 2, 7, 13 and 18 represent each probe incubated with
nuclear extracts. Lanes 3, 8, 14 and 19 represent each probe incubated with a 100-fold excess of the unlabeled competitor oligonucleotides. Lanes 4,
9, 15 and 20 represent each probe incubated with a 100-fold excess of the unlabeled mutant competitor oligonucleotides. Lanes 5, 10, 12 and 17
represent the EMSA results in the presence of anti-c-Myc antibody. The experiments were repeated three times. B. Binding of E-box sites to c-Myc in
vivo detected by ChIP. The Input lanes correspond to PCR products derived from chromatin prior to immunoprecipitation. The IgG lanes correspond
to PCR products containing chromatin immunoprecipitated with antibodies against control IgG. The c-Myc lanes correspond to PCR products
containing chromatin immunoprecipitated with antibodies against c-Myc. M indicates DNA 2000 marker. The 242 bp PCR product of c-Myc A or the
215 bp PCR product of c-Myc B is obtained corresponding to the sequence either E-box A or B binding site of the MYCT1-TV promoter. Results of
Hep2 cells shown in the left figure are in line with those of HEK293 cells in the right one.
doi:10.1371/journal.pone.0025648.g005
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25648Figure 6. Silencing of endogenous c-Myc reduces MYCT1-TV promoter activity. A. Detecting of c-Myc expression level in cells by qRT-PCR.
The expression of GAPDH was used as an internal control. Hundred nanogram of no siRNA (Mock), nonspecific control siRNA (NC) or c-Myc specific
siRNA (c-Myc) were transfected into Hep2 (black bars) or HEK293 (gray bars) cells. B. Luciferase activity of MYCT1-TV promoter after transfected with
c-Myc siRNA. Luciferase activity was measured in Hep2 (black bars) or HEK293 (gray bars) extracts 48 h after transfection. pGL3-Basic, cells
cotransfected with pGL3-Basic and pRL-TK; P852, cells cotransfected with P852 and pRL-TK; P852+NC, cells cotransfected with P852, NC siRNA and
pRL-TK; P852+c-Myc, cells cotransfected with P852, c-Myc siRNA and pRL-TK. Data are indicated as the means 6 SEM of three independent
experiments.
doi:10.1371/journal.pone.0025648.g006
Figure 7. Expression of MYCT1-TV and MYCT1 in human cells and tissues. A. MYCT1-TV mRNA levels in human cells. The gray-scale ratios of
MYCT1-TV to b-actin mRNA levels in Hep2, HeLa, BGC823, SGC7901, Bel7402, GES1, HEK293, human blood and MKN1 cells are 0.289060.0521,
0.311360.0138, 0.298560.0130, 0.296460.0427, 0.351260.0407, 1.052260.0808, 1.115960.1467, 1.164160.0665 and 0.234860.0147, respectively. B.
MYCT1-TV and MYCT1 mRNA levels in LSCC and paired adjacent normal laryngeal tissues. PCR produce a 929 bp DNA fragment for MYCT1-TV,a
726 bp DNA fragment for MYCT1 and a 511 bp DNA fragment for b-actin. The gray-scale ratios of MYCT1-TV to b-actin mRNA levels (black bars) in
LSCC and paired adjacent normal laryngeal tissues are 0.417260.0324 and 0.807360.0478, and the counterpart gray-scale ratios of MYCT1 to b-actin
mRNA levels (gray bars) are 0.430460.0304 and 0.841660.0499. M, T and R indicate DNA marker, LSCC tumor tissue and paired adjacent normal
tissue, respectively.
doi:10.1371/journal.pone.0025648.g007
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obtained in HEK293 cells, and the counterparts were
64.4763.40%,63.1465.08%and72.2965.62%(p.0.05,Fig.9A).
Cell apoptosis assay indicated that the proportion of early
apoptotic Hep2 cells was significantly higher in MYCT1-TV-GFP
or MYCT1-GFP group than those in blank and GFP groups
(p,0.01, Fig. 9B). The percentages of early apoptotic Hep2 cells in
blank, GFP, MYCT1-TV-GFP and MYCT1-GFP groups were
0.9260.25%, 1.1960.08%, 4.3760.96% and 3.6360.43%,
respectively. In addition, there was no obvious difference between
MYCT1-GFP-TV and MYCT1-GFP groups (p.0.05, Fig. 9B).
However, similar results were not detected in HEK293 cells
(p.0.05, Fig. 9B) and the counterparts were 0.8660.09%,
0.9760.27%, 0.7460.20% and 0.9360.25%, respectively.
Cell invasion assay displayed that the transmembrane Hep2
cells in MYCT1-TV-GFP or MYCT1-GFP group were signifi-
cantly fewer than those in blank and GFP groups (p,0.01,
Fig. 9C). The numbers of invasive Hep2 cells in blank, GFP,
MYCT1-TV-GFP and MYCT1-GFP groups were 31.3361.67,
28.3361.28, 11.5060.76 and 13.8361.45, respectively. More-
over, there was no obvious difference between MYCT1-TV-GFP
and MYCT1-GFP groups (p.0.05, Fig. 9C). Meanwhile similar
results were not observed in HEK293 cells (p.0.05, Fig. 9C) and
the counterparts were 12.3361.45, 10.0060.58, 8.6761.76 and
9.3361.20, respectively.
The results above imply that MYCT1-TV and MYCT1 have the
abilities in depressing proliferation and invasiveness, and promot-
ing apoptosis in Hep2 cells, but not in HEK293 cells.
Discussion
c-Myc, together with L-Myc, and N-Myc in the family of c-Myc
genes, was discovered as the cellular homolog of the retroviral v-
myc oncogene 30 years ago [15]. It is also known as a transcription
factor through forming heterodimers with its binding partner Max
either binding to the canonical E-box sequence CACGTG or to
several other noncanonical E-box motifs, such as CATGTG,
CATGCG, CACGCG, CACGAG, CGCGAG and CAACGTG
[11–14]. Dysregulated expression or function of c-Myc is one of
the most common abnormalities in human malignancy [16], such
as breast cancer [17], colorectal cancer [18,19], prostate cancer
[20,21], and hepatocellular carcinoma [22,23]. Overexpression of
the c-Myc oncogene has also been observed in LSCC [5,24]. In
mammalian cells, c-Myc expression is highly regulated and closely
tied to cell proliferation, growth, apoptosis and differentiation
[16,22].
Given the functions of c-Myc in various biological processes,
identification of c-Myc molecular targets has become a hotspot in
molecular genetics and oncology research. To date, a large
number of c-Myc target genes which could recapitulate c-Myc
functions have been confirmed, such as Cdk4, HMG-I/Y, CAD,
Cdc25A, ODC, LDH-A, rcl, Gadd45, P53, Tmp and mt-mc1 [12,25–
28]. For example, mt-mc1, rcl and LDH-A can promote cell
transformation and tumorigenesis [28,29], mt-mc1, Cdc25A, P53
and Gadd45 can induce apoptosis [28,30–32], P53, Gadd45 and
Cdk4 can arrest cell cycle [31–33]. These genes have one common
feature, in which they all have E-box elements in their promoter
regions for c-Myc binding.
Our previously study characterized that there are two putative
E-box elements in the 59 flanking sequence of MYCT1 [9], but it
has not been proved by experiment. To address this question, we
cloned a 864 bp promoter ranges from position 2852/+12
relative to the identified TSS. This only TSS is located at
140 bp upstream of the ATG start codon of MYCT1-TV.
Luciferase reporter assays showed that this promoter (2852/
+12) which efficiently drove luciferase expression in transiently
transfected Hep2 and HEK293 cells was functional and exhibited
greater transcriptional activity in the presence of two E-box
elements. The consistent transcriptional activities of this 864 bp
promoter in tumor and normal cells we tested indicated that
ubiquitous E-box elements are involved in regulation of MYCT1-
TV gene transcription. EMSA and ChIP assays showed that c-Myc
protein extracted from Hep2 or HEK293 cells can specifically
bind to either E-box element between 2852 bp and 2667 bp
region. Furthermore, transcriptional activity of MYCT1-TV
promoter can be reduced either by site-directed mutagenesis or
by c-Myc siRNA transfection, which means c-Myc can specifically
enhance MYCT1-TV promoter activity. These results provide the
support that c-Myc is the important transcription factor for
MYCT1-TV promoter.
By bioinformatics analysis we found that MYCT1-TV encodes
a 187 amino acid protein which is part of 235 amino acid protein
encoded by MYCT1 and the shorter 48 amino acid protein
contains no obviously structural or functional motif. Since
MYCT1-TV and MYCT1 have no structural difference, we are
interested in whether they have functional differences. We then
detected the expression and biological variation of MYCT1-TV
and MYCT1 by RT-PCR, cell proliferation, apoptosis and
invasion assays.
Invasion and metastasis are the characteristics of malignant
tumours, which are responsible for the primary cause of death in
cancer patients. The migration and invasion mechanisms of
cancer cells begin with the growth of cancer cells at the primary
site of development, followed by decreased local invasion through
the surrounding tissue. The larger the primary tumour grows, the
more likely that the tumour will be able to acquire traits that lead
to a metastatic phenotype. Therefore, inhibition of the invasion
and metastasis of tumour cells is a crucial step which would be a
useful pathway in the treatment of cancer patients [34–39]. Our
present study showed that overexpression of MYCT1-TV/MYCT1
in Hep2 cells could promote cells apoptosis and inhibit cells
proliferation and invasion. We speculated this MYCT1-TV/
MYCT1 properties in inhibiting the invasiveness of Hep2 cells
probably result from their function on promotion of apoptosis and
Table 1. Analysis of the relationship between MYCT1-TV/
MYCT1 and clinical characteristics (Gray-scale ratio, mean 6
SEM).
mRNA levels
Characteristic Response MYCT1-TV MYCT1
Age ,62 y 0.436760.0562 0.448060.0524
$62 y 0.399560.0361 0.414460.0143
P=0.936 P=0.789
Sex Male 0.443860.0425 0.443360.0372
Female 0.669560.1051 0.394060.0558
P=0.069 P=0.405
Cancer stage I 0.579560.0954 0.475560.0730
II 0.388960.0518 0.487260.0843
III 0.397760.0776 0.417560.0597
IV 0.369560.0400 0.387560.0453
P=0.123 P=0.695
doi:10.1371/journal.pone.0025648.t001
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25648Figure 8. Transfection of MYCT1-TV and MYCT1 in Hep2 and HEK293 cells. A. mRNA levels of MYCT1-TV/MYCT1 in Hep2 and HEK293 cells
transfected with MYCT1-TV-GFP/MYCT1-GFP. PCR produce a 929 bp DNA fragment for MYCT1-TV, a 726 bp DNA fragment for MYCT1 and a 511 bp
DNA fragment for b-actin. In Hep2 cells, the gray-scale ratios of MYCT1-TV to b-actin mRNA levels (black bars) in blank, GFP and MYCT1-TV-GFP
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proliferation in Hep2 cells by suppressing cells apoptosis may
promote the migration and invasion abilities of Hep2 cells.
However, both MYCT1-TV and MYCT1 displayed lower expres-
sion in cancer tissues than that in adjacent normal tissues. We also
found that MYCT1-TV and MYCT1 do not affect the proliferation,
apoptosis and invasion of HEK293 cells. These findings imply that
MYCT1-TV and MYCT1 display TSGs-like properties and the
down-regulation of them in LSCC perhaps bring about increased
proliferation, decreased apoptosis and stepped up invasiveness of
tumour cells which may facilitate laryngeal carcinogensis.
The oncogene c-Myc which is overexpressed in LSCC [5,24]
can specifically activate MYCT1-TV and MYCT1 promoter
activities, but MYCT1-TV and MYCT1 which appear TSGs-like
properties are down-regulated in LSCC. Thus we inferred that
MYCT1-TV/MYCT1 may silence through MYCT1-TV/MYCT1
promoter methylation in the absence of c-Myc overexpression,
which is associated with cancer progression. Alternatively, other
transcription factors could be involved in MYCT1-TV/MYCT1
regulation. This may be the reason for the lower expression and
TSGs-like properties of MYCT1-TV/MYCT1 in LSCC tissues or
cells. The specific mechanism need to be further verified.
Results from cells viability and apoptosis assays demonstrated
that the overexpression of MYCT1-TV/MYCT1 could decrease
proliferation of Hep2 cells, but increase apoptosis of Hep2 cells.
Given these findings, we suggested that as candidate c-Myc target
genes, MYCT1-TV and MYCT1 really have some of the known
phenotypic features associated with c-Myc, but whether they have
the other properties of c-Myc and the precise mechanism between
c-Myc and MYCT1-TV/MYCT1V need to be further studied.
As newly discovered genes, MYCT1-TV and MYCT1 showed no
significant differences in the expression or biological function in
LSCC or cells. Maybe both of them should be the main forms for
MYCT1 to achieve its function efficiently. At present, the role of
MYCT1-TV and MYCT1 is unceasingly studied. Our present study
provides a fundamental clue for the further exploration on
understanding the function and the molecular mechanism of
MYCT1-TV/MYCT1 in LSCC.
Materials and Methods
Cell culture
The human laryngeal cancer cells Hep2, the human hepatoma
cells Bel7402, the human epithelial carcinomacells HeLa, the human
gastric carcinoma cells BGC823, SGC7901 and MKN1, and the
human gastric epithelial cells GES1 were grown in complete RPMI
1640 medium containing 10% fetal bovine serum. The human
embryonic kidney cells HEK293 were maintained in Dulbecco’ s
high glucose modified Eagle’ s medium (DMEM) containing 10%
fetal bovine serum. All the cells above were purchased from Cell
Biology Institute of Shanghai, Chinese Academy of Science.
Samples
Forty cases of LSCC tissues were obtained from patients treated
at the Ear, Nose and Throat (E.N.T) department of the 463
Hospital of PLA of China after receiving their written informed
consentandthe approvalofthehospitalauthorities.Nopatientshad
previously received any neoadjuvant treatment, e.g. chemotherapy,
before the surgery. The specimens, including cancerous tissues and
paired adjacent normal laryngeal tissues typically 4–15 mm in
diameter were obtained during diagnostic biopsy or operation, and
confirmed by pathologists. The clinical pathological characteristics
of the patients were evaluated according to the International Union
Against Cancer guidelines. All specimens were frozen immediately
after surgery and stored at 280uC. Approval for the study was
received from the Ethics Committee of China Medical University.
Patient information is shown in Table 2.
Rapid Amplification of cDNA Ends (RACE)
The 59 and 39 end of the gene was elucidated by RACE-PCR
using the SMART
TM RACE cDNA amplification kit (Clontech,
Heidelberg, Germany), according to the manufacturer’ s protocol.
Total RNA was extracted from normal human blood by an RNA
extraction kit (Galen Biopharm, Beijing). The first round PCR of
59 RACE was performed with the Universal Primer A Mix UPM
obtained from the kit and the gene-specific primer GSP1 (59-CAT
AGG CAG GTG GGG GCG GTG TT-39). PCR product was
used in a secondary nested PCR with the Nested Universal Primer
A NUP obtained from the kit and the nested gene-specific primer
NGSP1 (59-TGG ACC AGT AGT CAG GAC GGC TCA GA-
39). The 39-cDNA ends were amplified using the first primer pair
GSP2 (59-TAT CCA TGG CAA TCG GGC TGG TAC T-39)
and UPM followed by a nested PCR with the second primer pair
NGSP2 (59-AGT GGC TGT GAA CGT CGA AGC AAC C-39)
and NUP. The obtained new MYCT1 transcript variant was
deposited in GenBank (MYCT1-TV, GenBank accession
No. GU997693).
Sequence prediction and analysis of MYCT1
A series of bioinformatics softwares were used as follows: BDGP
(www.fruitfly.org /seq_tools/promoter.html); Promoter 2.0 (www.
cbs.dtu.dk/services/Promoter/); Promoter Scan (www-bimas.cit.
nih.gov/molbio/proscan/); ExPASy proteomics server (http://
www.expasy.org/tools/dna.html); NCBI blast (http://blast.ncbi.
nlm.nih. gov/Blast.cgi).
Plasmid construction
For cloning of the MYCT1 promoter-driven reporter plasmid,
genomic DNA was prepared from the human blood using the
TIANamp Genomic DNA Kit (Tiangen, China). Plasmids used
for functional analysis of the MYCT1 promoter activity were
generated using the promoterless luciferase reporter plasmid
pGL3-Basic (Promega, USA). Three 59 deletion constructs of
P852 (2852/+12), P799 (2799/+12), and P667 (2667/+12) were
generated by PCR amplification method. Three different forward
primers contained an internal site for SacI restriction enzyme each
and their sequences are: primer 852: 59-TTT GAG CTC GTG
GCC GAG CGC AGT-39; primer 799: 59-TTT GAG CTC GCA
GGT GGA TCA CTT GAG G-39; and primer 667: 59-TTT
GAG CTC GCT GAG GCA GGA GAA TCG-39. The sequence
groups are 0.473560.0335, 0.431560.0303 and 23.518862.0896, and the gray-scale ratios of MYCT1 to b-actin mRNA levels (gray bars) in blank, GFP
and MYCT1-GFP groups are 0.415760.1080, 0.424260.0658 and 25.752061.3244, respectively. In HEK293 cells, the counterpart gray-scale ratios of
MYCT1-TV to b-actin mRNA levels are 1.307160.2223, 1.252360.1002 and 32.033962.2903, and the counterpart gray-scale ratios of MYCT1 to b-actin
mRNA levels are 0.995060.0725, 1.144860.1346 and 31.516161.9808, respectively. B. Transfection efficiency and expression of MYCT1-TV/MYCT1
protein in Hep2 and HEK293 cells. Transfection efficiency and expression of MYCT1-TV/MYCT1 protein in GFP, MYCT1-TV-GFP and MYCT1-GFP groups
are revealed by contrast and fluorescence microscopy under the same phase. M, DNA marker; blank, control cells before transfection; GFP, control
cells after transfection with GFP only; MYCT1-TV-GFP, cells transfected with MYCT1-TV-GFP; MYCT1-GFP, cells transfected with MYCT1-GFP
(**, p,0.01).
doi:10.1371/journal.pone.0025648.g008
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TTT AAG CTT GTT ATT AGC CAT AAT ATC CAC AAG
A-39.
Mutated reporter plasmids were generated by using the Gene
Tailor site-directed mutagenesis system (Invitrogen, USA), ac-
cording to the manufacturer’ s instructions using primers designed
to replace the E-box A core sequence ‘‘CGCATG’’ with
‘‘TTCATG’’ (named P852-mutA), replace the E-box B core
sequence ‘‘CACGCG’’ with ‘‘CAAGGG’’ (named P852-mutB)
and replace both E-box core sequences above (named P852-
mutAB). The mutated sequences were cloned into the SacI/
HindIII site of pGL3-Basic vectors.
Luciferase and RNAi assays
Cells in 24-well plates were transfected in triplicate using
Lipofectamine 2000 (Invitrogen, USA) with 0.8 mg, respectively, of
specific plasmids. After 48 h of transfection, cells were harvested in
100 ml of Passive Lysis Buffer (Promega) and luciferase assay was
performed using the Dual Luciferase Assay System (Promega,
USA) according to the manufacturer’ s instructions. Relative
luciferase activity was calculated as the ratio of sample luciferase
activity to renilla luciferase activity. Values are expressed as fold
changes versus pGL3-Basic.
The c-Myc translation was silenced in Hep2 and HEK293 cells
using the siRNA duplexes c-Myc siRNA (59-GUG CAG CCG
UAU UUC UAC UTT-39) synthesized by Gene Pharma. A
nonspecific siRNA (59-UUC UCC GAA CGU GUC ACG UTT-
39, Gene Pharma) was used as negative control (NC). Cells were
transfected with 20 pmol of siRNA, 0.2 mg of P852, P799 or
empty construct of the luciferase reporter gene, and 16 ng pRL-
TK were cotransfected into cells using Lipofectamine 2000
(Invitrogen, USA) following the manufacturer’s instructions. The
results of gene knockdown were determined by real time
quantitative reverse transcription PCR (qRT-PCR) using Ver-
iQuest
TM SYBR Green (USB) and luciferase reporter activity was
determined at 48 h after transfection.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from Hep2 and HEK293 cells
using a nuclear extract kit (Active Motif, USA) following the
manufacturer’s instructions. The following double-stranded oligo-
nucleotides were used (wild type and mutant binding sites are
underlined): E-box A, 59-CGA GCG CAG TGG CGC ATG
GCT GTA ATC CCA-39; E-box B, 59-CGG GTG TGG TGG
CAC GCG CCT GTA ATC CCA-39; E-box A mutant, 59-CGA
GCG CAG TGG CAT GGG GCT GTA ATC CCA-39; E-box B
mutant, 59-CGG GTG TGG TGG CGT TAG CCT GTA ATC
CCA-39. Oligonucleotide labeling was performed using the Biotin
39 End Labeling Kit (Pierce, USA). EMSA used the Lightshift
Chemiluminescent EMSA kit (Pierce, USA) according to the
protocols provided. For competition assays, samples were
preincubated with a 100-fold excess of the unlabeled wild type
or mutated oligonucleotide duplex competitors. For the supershift
reaction, 1 mg of each anti-c-Myc antibody (N-262X, Santa Cruz)
was preincubated with the nuclear extracts in the absence of poly
(dI?dC) for 1 hour at 4uC. Subsequently, poly (dI?dC) was added
and incubated for 5 min, followed by the addition of a probe for
an additional 20 min. Protein DNA complexes were separated by
electrophoresis on a 6% non-denaturing acrylamide gel in
0.56TBE, transferred to positively charged nylon membranes,
and visualized by streptavidin-horseradish peroxidase followed by
chemiluminescent detection (Pierce, USA).
Chromatin immunoprecipitation assay (ChIP)
ChIP assay were performed as previously described [40,41].
Cells were fixed with 1% formaldehyde in growth medium at 37uC
for 10 min. After washed with ice-cold PBS, cells were lysed with
lysis buffer containing protease inhibitors and sonicated to obtain
DNA fragments. Small amount of DNA fragments was saved as
input DNA. The rest was diluted, treated with anti-c-Myc
antibody (N-262X, Santa Cruz) or rabbit IgG, and immunopre-
cipitated by protein A/G plus-agarose (Santa Cruz, USA). Each
precipitated DNA was eluted and extracted with phenol-
chloroform and subjected for PCR. PCR was performed with
MYCT1 promoter-specific primers amplifying the c-Myc binding
regions (c-Myc A, forward, 59-GTT TTC CCT CCT TGA TTT-
39, and reverse, 59-GTG ATC CAC CTG CTT TG-39; c-Myc B,
forward, 59-GAG GTC AGG CCT AGT TCA TG-39, and
reverse, 59-CTT AGT CTC GCT CTG TCG C-39).
Construction of MYCT1-TV-GFP and MYCT1-GFP
expression vectors
The entire open reading frames of MYCT1-TV and MYCT1
complementary DNA (cDNA) were obtained by RT-PCR from
normal human blood. The associated primer sequences are as
follows: MYCT1-TV-GFP, forward, 59-TTT GTC GAC ATG
GCT AAT AAC ACA ACA AGT TTA G-39, and reverse, 59-
TTT GGA TCC TCA GGA ATC TGG GAA TGC C-39;
MYCT1-GFP, forward, 59-TTT GTC GAC ATG CGA ACA
CAA GTA TAT GAG GGG T-39, and reverse, 59-TTT GGA
TCC TCA GGA ATC TGG GAA TGC C-39. Two different
forward primers contains a SalI site and two different reverse
primers contains a BamHI site. The PCR fragments were cloned
into the SalI/BamHI site of pEGFP-C1 plasmids (BD, USA). The
fidelity of the constructs was then confirmed by sequencing, and
plasmids were prepared for transfection using TIANpure Mini
Plasmid Kit (Tiangen, China). MYCT1-TV-GFP, MYCT1-GFP
and pEGFP-C1 vectors (as a negative control) were then
transfected into Hep2 cells and HEK293 cells using Lipofectamine
2000 (Invitrogen, USA) following the manufacturer’ s instructions.
Figure 9. Function of MYCT1-TV and MYCT1 in Hep2 and HEK293 cells. The proliferation of Hep2 and HEK293 cells. B. The apoptosis of Hep2
and HEK293 cells. C. The invasive ability of Hep2 and HEK293 cells. Blank, control cells before transfection; GFP, control cells after transfection with
GFP only; MYCT1-TV, cells transfected with MYCT1-TV-GFP; MYCT1, cells transfected with MYCT1-GFP.
doi:10.1371/journal.pone.0025648.g009
Table 2. The characteristics of the patients (n=40).
Characteristic Response Cases (%)
Age ,62 y 19 (47.5)
$62 y 21 (52.5)
Sex Male 28 (70.0)
Female 12 (30.0)
Cancer stage I 7 (17.5)
II 8 (20.0)
III 10 (25.0)
IV 15 (37.5)
doi:10.1371/journal.pone.0025648.t002
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reaction (RT-PCR)
Total RNA was isolated from Bel7402 cells, Hep2 cells, HeLa
cells, BGC823 cells, SGC7901 cells, MKN1 cells, GES1 cells,
HEK293 cells, human blood, LSCC tissues and paired adjacent
normal laryngeal tissues using Trizol reagent (Invitrogen, USA)
following the protocol of the manufacturer. cDNA was synthesized
by reverse transcription using an AMV RNA PCR kit (TaKaRa,
China) in keeping with the standard operating procedure. The
MYCT1 primers were the same as those for construction of
MYCT1-GFP, which were expected to produce a 726 bp DNA
fragment. The primers for MYCT1-TV were 59- TAA TAA CAC
AAC AAG TTT AGG GAG T and 59-AGT CAC ATT GGA
AGT AAA TGA GGA TTG-39, which were expected to produce
a 929 bp DNA fragment. b-actin served as an internal control in
each sample. The primer sequences for b-actin were 59-CTC
TTC CAG CCT TCC TTC CT-39 and 59-CAC CTT CAC
CGT TCC AGT TT-39, which were expected to produce a
511 bp DNA fragment. The electrophoresis images were scanned
by Fluor-S MultiImager (Bio-Rad, USA) and the original intensity
of each specific band was quantified with the software Multi-
Analyst (Bio-Rad, USA). Data were analyzed after being
normalized by the intensity of b-actin.
Cell viability assay
Cell viability was assessed by the MTT colorimetric assay.
50 mg of MTT (Sigma, USA) was dissolved in 10 mL of PBS.
After being seeded for 24 h in a 96-well plate, Hep2 and HEK293
cells (1610
4 cells/well) were transfected with GFP only, MYCT1-
TV-GFP and MYCT1-GFP for 48 h, with untransfected cells
serving as a control. At 48 h after transfection, 10 ml of MTT
solution (5 mg/mL) was added to each well. After incubation for
4 h at 37uC, the medium was replaced with 200 ml of DMSO and
the plate was allowed to shake on a plate shaker for 10 min.
Absorbance at 490 nm was measured using a microplate reader,
and the results were expressed as a percentage (%) of the control.
All experiments were done with three parallel wells each and
repeated three times [42].
Apoptosis assay
Apoptotic cells were measured by using an annexin V-PE/7-
AAD Kit (KeyGEN, China) according to the manufacturer’s
protocol. The apoptotic rates were analysed by flow cytometry on
a FACS Calibur (Becton Dickinson, USA). Cells that were annexin
V-PE positive and 7-AAD negative indicated early apoptotic cells
[42].
Transwell chamber invasion assay
Twenty-four-well invasion chambers were obtained from Costar
(USA). After being transfected with negative control GFP,
MYCT1-TV-GFP, and MYCT1-GFP, Hep2 (2610
5 cells) and
HEK293 (4610
5 cells) cells were detached and resuspended in
serum-free medium, and seeded to the upper chambers. 500 mlo f
medium containing 10% FBS was added to the lower chambers.
After incubation at 37uC for 24 h, cells remaining attached to the
upper surface of the filters were carefully removed with cotton
swabs. The filters were fixed with methanol and stained with
haematoxylin and eosin. The cells that invaded to the underside of
the filter were counted [43].
Statistics
Data were subjected to statistical analysis and shown as mean 6
standard error of the mean (SEM). Differences in mean values
were analyzed using one-way analysis of variance (ANOVA).
Comparisons related to age or sex in clinical characteristics were
made by the Mann-Whiney U test. The comparisons of mRNA
levels between MYCT1-TV and MYCT1 in LSCC and paired
adjacent normal laryngeal tissues were made by Levene’s test. In
the figures, the statistically significant values were marked with
asterisks (*, p,0.05; **, p,0.01).
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